Page 11 - BH-2-4

Brain & Heart Cardiac sarcoidosis with AVB and VA

Table 2. Studies related to VAs and AVB in patients with CS
Author Place of Type of study No. of No. of patients Endpoints/outcomes Key findings
study patients with with VAs
AVB
Ekström et al. Finland Case Series 147 48 Endpoint event was death Overall, 80% of deaths from CS were
2019 6 from any cause sudden cardiac death. AVB was the
most common presentation, and
the diagnosed patients showed a
5-year survival rate of 85%, which
improved to 93% after receiving
immunosuppressive therapy
Rosenthal et al. USA Prospective, 58 152 Endpoint was diagnosis of Sarcoidosis is the strongest risk
2021 9 multicenter cohort either heart failure, AVB, factor for the development of VT and
VT, or death in patients AVB (no specific data available on
with CS prognosis after these presentations)
Hoogendoorn Netherlands Case Series 4 10 Review of ejection Early diagnosis of CS and initiation
et al. 2020 10 fractions and clinical of immunosuppressive therapy are
outcomes (death, critical to improving prognosis in
hospitalization for heart patients referred for VT ablation
failure, VT ablation) with non-ischemic cardiomyopathy
over time in early vs. late
diagnosis of CS
Nery et al. Canada Prospective, 11 - Diagnosis of CS in In patients presenting with AVB,
2014 11 single-center cohort patients with second- or patients with CS have more adverse
third-degree AVB and no clinical outcomes than those without
history of sarcoidosis in
another organ. Additional
observed adverse events
(heart failure, VT)
Cacoub et al. France Retrospective, 27 27 Assessed relapse-free High-degree AVB in patients with
2020 23 single-center cohort survival, where relapse CS is associated with increased
was defined as any new mortality. IV cyclophosphamide is
cardiac or non-cardiac associated with lower rates of cardiac
symptom attributed relapse
to sarcoidosis by the
patient’s physician
Kaida et al. Japan Retrospective, 15 - Review of LVEF and brain Early diagnosis of CS in patients
2018 24 single-center Cohort natriuretic peptide levels presenting with complete AVB
over time in early vs. late significantly improves prognosis
CS diagnosis
Zhou et al. USA Retrospective 14 26 Primary endpoints were Lack of permanent pacemaker/ICD
2016 28 single-center cohort death and heart transplant. and age were significant predictors of
Recorded rates of reduced mortality for patients with CS
LVEF, VA, AVB
Yodogawa et al. Japan Retrospective, - 8 Evaluation of the location LGE in the RV free wall was
2022 29 single-center cohort of LGE in patients with CS associated with the development of
who presented with VAs VAs in patients with CS
Kato et al. Japan Retrospective 20 9 in follow-up Outcomes measured were Corticosteroids are useful in the
2003 32 single-center cohort period death; improvement/ treatment of CS with AVB, leading
resolution of AVB; change to resolution in 57% of the patients.
in LVEF, VT, and side Steroids may also play a role in
effects of corticosteroids preventing VT
Sadek et al. Japan, USA, Systematic Review 57 - Outcomes examined Corticosteroids can be effective for
2013 33 Europe were atrioventricular treating AVB, with 47.4% of the
conduction, LVEF, VAs, patients showing improvement. Not
and mortality enough data to draw conclusions
regarding VAs
(Cont’d...)

Volume 2 Issue 4 (2024) 5 doi: 10.36922/bh.3515